Filing Details

Accession Number:
0001104659-23-067645
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-02 17:05:55
Reporting Period:
2023-05-31
Accepted Time:
2023-06-02 17:05:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819576 Liquidia Corp LQDA Pharmaceutical Preparations (2834) 851710962
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1832592 Scott Moomaw 419 Davis Drive,
Suite 100
Morrisville NC 27560
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-31 1,875 $0.00 102,919 No 4 M Direct
Common Stock Disposition 2023-05-31 651 $8.08 102,268 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2023-05-31 1,875 $0.00 1,875 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,625 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  2. On January 16, 2022, the Reporting Person was granted 30,000 RSUs with 25% vesting on February 28, 2023, with the remaining RSUs vesting ratably on a quarterly basis over three years thereafter. Of those RSUs, a total of 9,375 have vested through May 31, 2023.
  3. Includes (i) 83,333 RSUs granted to the Reporting Person on January 11, 2023, none of which have vested as of the date of this Form 4 and (ii) 4,732 shares previously acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
  4. These shares were sold to cover taxes associated with the settlement of RSUs.
  5. Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2022.